Literature DB >> 34982284

Exosome application in tumorigenesis: diagnosis and treatment of melanoma.

Mohsen Karami Fath1, Ali Azargoonjahromi2, Nafiseh Jafari3, Maryam Mehdi4, Fatemeh Alavi5, Mona Daraei6, Niloufar Mohammadkhani7, Anna-Lena Mueller8, Aranka Brockmueller8, Mehdi Shakibaei9, Zahra Payandeh10.   

Abstract

Melanoma is the most aggressive of skin cancer derived from genetic mutations in the melanocytes. Current therapeutic approaches include surgical resection, chemotherapy, photodynamic therapy, immunotherapy, biochemotherapy, and targeted therapy. However, the efficiency of these strategies may be decreased due to the development of diverse resistance mechanisms. Here, it has been proven that therapeutic monoclonal antibodies (mAbs) can improve the efficiency of melanoma therapies and also, cancer vaccines are another approach for the treatment of melanoma that has already improved clinical outcomes in these patients. The use of antibodies and gene vaccines provides a new perspective in melanoma treatment. Since the tumor microenvironment is another important factor for cancer progression and metastasis, in recent times, a mechanism has been identified to provide an opportunity for melanoma cells to communicate with remote cells. This mechanism is involved by a novel molecular structure, named extracellular vesicles (EVs). Depending on the functional status of origin cells, exosomes contain various cargos and different compositions. In this review, we presented recent progress of exosome applications in the treatment of melanoma. Different aspects of exosome therapy and ongoing efforts in this field will be discussed too.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biomarker; CTLA-4; Exosome; Immunotherapy; Melanoma; Signaling pathways

Mesh:

Substances:

Year:  2022        PMID: 34982284     DOI: 10.1007/s12032-021-01621-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  122 in total

Review 1.  Antigen-processing machinery breakdown and tumor growth.

Authors:  B Seliger; M J Maeurer; S Ferrone
Journal:  Immunol Today       Date:  2000-09

Review 2.  Immune escape mechanisms as a guide for cancer immunotherapy.

Authors:  Gregory L Beatty; Whitney L Gladney
Journal:  Clin Cancer Res       Date:  2014-12-12       Impact factor: 12.531

Review 3.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

4.  Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.

Authors:  Esther P M Tjin; Gabrielle Krebbers; Kimberley J Meijlink; Willeke van de Kasteele; Efraim H Rosenberg; Joyce Sanders; Petra M Nederlof; Bart A van de Wiel; John B A G Haanen; Cornelis J M Melief; Florry A Vyth-Dreese; Rosalie M Luiten
Journal:  Cancer Immunol Res       Date:  2014-03-10       Impact factor: 11.151

5.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

6.  Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.

Authors:  Ana B del Campo; Jon Amund Kyte; Javier Carretero; Svitlana Zinchencko; Rosa Méndez; Gloria González-Aseguinolaza; Francisco Ruiz-Cabello; Steinar Aamdal; Gustav Gaudernack; Federico Garrido; Natalia Aptsiauri
Journal:  Int J Cancer       Date:  2013-07-16       Impact factor: 7.396

Review 7.  Melanoma: from melanocyte to genetic alterations and clinical options.

Authors:  Corine Bertolotto
Journal:  Scientifica (Cairo)       Date:  2013-12-12

Review 8.  Immune system and melanoma biology: a balance between immunosurveillance and immune escape.

Authors:  Anna Passarelli; Francesco Mannavola; Luigia Stefania Stucci; Marco Tucci; Francesco Silvestris
Journal:  Oncotarget       Date:  2017-10-31

9.  Evidence That Tumor Microenvironment Initiates Epithelial-To-Mesenchymal Transition and Calebin A can Suppress it in Colorectal Cancer Cells.

Authors:  Constanze Buhrmann; Aranka Brockmueller; Choudhary Harsha; Ajaikumar B Kunnumakkara; Peter Kubatka; Bharat B Aggarwal; Mehdi Shakibaei
Journal:  Front Pharmacol       Date:  2021-07-02       Impact factor: 5.810

10.  Cytokines and growth factors expressed by human cutaneous melanoma.

Authors:  Elias G Elias; Joanne H Hasskamp; Bhuvnesh K Sharma
Journal:  Cancers (Basel)       Date:  2010-05-07       Impact factor: 6.639

View more
  3 in total

1.  Rothia nasimurium as a Cause of Disease: First Isolation from Farmed Geese.

Authors:  Yuhui Kang; Hongshan Zhou; Wenjie Jin
Journal:  Vet Sci       Date:  2022-04-21

Review 2.  Urine exosomes as biomarkers in bladder cancer diagnosis and prognosis: From functional roles to clinical significance.

Authors:  Nicholas Lee; Ashan Canagasingham; Mohit Bajaj; Ramesh Shanmugasundaram; Anthony Hutton; Joseph Bucci; Peter Graham; James Thompson; Jie Ni
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

Review 3.  Current understanding of epigenetics role in melanoma treatment and resistance.

Authors:  Mohsen Karami Fath; Ali Azargoonjahromi; Asma Soofi; Faezeh Almasi; Shahnaz Hosseinzadeh; Saeed Khalili; Kamran Sheikhi; Saeid Ferdousmakan; Soroor Owrangi; Minoovash Fahimi; Hamidreza Zalpoor; Mohsen Nabi Afjadi; Zahra Payandeh; Navid Pourzardosht
Journal:  Cancer Cell Int       Date:  2022-10-12       Impact factor: 6.429

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.